Trastuzumab-Deruxtecan (T-DXd) Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Trastuzumab-Deruxtecan (T-DXd) comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Breast Neoplasms. Most recent publication: TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases., Future Oncol, 2025.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases.
    Marhold M, Vaz Batista M, Blancas I, et al. · Future Oncol · 2025

Publications by year

20252025: 1 publications.

2025
1

Publications by indication

Breast Neoplasms (1)

  • TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases.
    Future Oncol · 2025 · PMID 40018758 · NCT06048718

Publications by journal

All Trastuzumab-Deruxtecan (T-DXd) publications (1)

2025 (1 paper)

  1. TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases.
    Marhold M, Vaz Batista M, Blancas I, et al. · Future Oncol · 2025 · Derived

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).